Is RDNT a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The site-of-care shift out of hospitals, with revenue (ttm) at ~$1.9B. The bear case rests on reimbursement is set largely by Medicare and by commercial contracts, so a rate cut or an unfavorable contract renewal flows almost straight to operating income. Analysts covering it are spread from $65.00 to $100.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Reimbursement is set largely by Medicare and by commercial contracts, so a rate cut or an unfavorable contract renewal flows almost straight to operating income. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $65.00, -10.2% from the $72.39 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The site-of-care shift out of hospitals. A hospital outpatient department typically bills far more for the same MRI or CT than a freestanding center does, so insurers and employers have steadily steered volume toward independent imaging. The most optimistic analyst target on RDNT is $100.00, +38.1% from the $72.39 price. That figure is only reachable if this thesis works close to its best case.

Reimbursement is set largely by Medicare and by commercial contracts, so a rate cut or an unfavorable contract renewal flows almost straight to operating income. The business is capital intensive: scanners, buildings and IT require ongoing spending, and roughly $1.93B of debt against roughly $455M of cash means interest expense is a permanent line item and refinancing conditions matter. Trailing twelve month net income has been slightly negative, so valuation rests on adjusted EBITDA, free cash flow and the Digital Health growth story rather than on reported earnings. Radiologist supply is tight and labor cost inflation has been a persistent pressure across the industry. Finally, the AI segment faces credible competition from imaging equipment makers and well-funded startups, and if it stays a small share of revenue the company gets valued like the capital-heavy services business it mostly still is. The most pessimistic published target is $65.00, -10.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Largest US freestanding outpatient imaging network, layering an AI diagnostics segment on top of the scanning business.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The site-of-care shift out of hospitals) stalling in the reported numbers rather than in the narrative, the risk above (reimbursement is set largely by Medicare and by commercial contracts, so a rate cut or an unfavorable contract renewal flows almost straight to operating income) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It owns and operates freestanding outpatient diagnostic imaging centers across the United States, performing MRI, CT, PET, mammography, ultrasound and X-ray. Many centers are joint ventures with local hospitals and health systems. A second segment, Digital Health, builds and sells radiology AI and imaging workflow software under the DeepHealth brand.

RadNet trades on the Nasdaq under the ticker RDNT as a US common stock. Any US brokerage that supports Nasdaq-listed equities can route an order, and fractional share support depends on the individual broker rather than on the stock itself.

On an adjusted EBITDA basis, yes, with roughly $63.3M in the first quarter of 2026. On a GAAP basis the trailing twelve month net income has been slightly negative, around negative $18.7M, because depreciation on the scanner fleet, interest expense on close to $1.93B of debt and stock compensation absorb the operating profit.